Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

114.46USD
8 Dec 2017
Change (% chg)

$7.68 (+7.19%)
Prev Close
$106.78
Open
$113.15
Day's High
$116.32
Day's Low
$111.63
Volume
1,542,776
Avg. Vol
620,376
52-wk High
$149.17
52-wk Low
$96.18

Chart for

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $31,536.07
Shares Outstanding(Mil.): 223.19
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

Elliott Management seeks changes at Alexion - NYT

U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals , is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

08 Dec 2017

UPDATE 2-Elliott Management seeks changes at Alexion - NYT

Dec 8 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

08 Dec 2017

CORRECTED-Elliott Management seeks changes at Alexion - NYT (Dec. 7)

Dec 7 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

08 Dec 2017

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

07 Dec 2017

BRIEF-Alexion receives new Japanese patent for Soliris

* Alexion receives new Japanese patent for Soliris® (eculizumab), extending patent protection into 2027 and strengthening global patent portfolio Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Alexion reports Q3 non-GAAP earnings per share of $1.44

* Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S

26 Oct 2017

RPT-BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

13 Sep 2017

BRIEF-Interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

13 Sep 2017

Alexion Pharma to lay off 20 percent of workforce

Alexion Pharmaceuticals Inc said on Tuesday it would lay off about 20 percent of its workforce and sharpen its focus on its core rare disease drugs business, as it looks to restore investor confidence.

12 Sep 2017

UPDATE 2-Alexion Pharma to lay off 20 pct of workforce

* Drugmaker's shares down slightly (Adds details, analyst comment, updates share price)

12 Sep 2017

Competitors

Earnings vs. Estimates